ATE361760T1 - Verbesserungen in der bereitung von prodrogen - Google Patents

Verbesserungen in der bereitung von prodrogen

Info

Publication number
ATE361760T1
ATE361760T1 AT94921729T AT94921729T ATE361760T1 AT E361760 T1 ATE361760 T1 AT E361760T1 AT 94921729 T AT94921729 T AT 94921729T AT 94921729 T AT94921729 T AT 94921729T AT E361760 T1 ATE361760 T1 AT E361760T1
Authority
AT
Austria
Prior art keywords
pct
ftli
sec
prt
date
Prior art date
Application number
AT94921729T
Other languages
English (en)
Inventor
Caroline Joy Springer
Richard Marais
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Application granted granted Critical
Publication of ATE361760T1 publication Critical patent/ATE361760T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
AT94921729T 1993-07-27 1994-07-27 Verbesserungen in der bereitung von prodrogen ATE361760T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939315494A GB9315494D0 (en) 1993-07-27 1993-07-27 Improvements relating to prodrugs

Publications (1)

Publication Number Publication Date
ATE361760T1 true ATE361760T1 (de) 2007-06-15

Family

ID=10739484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94921729T ATE361760T1 (de) 1993-07-27 1994-07-27 Verbesserungen in der bereitung von prodrogen

Country Status (12)

Country Link
US (1) US5770731A (de)
EP (1) EP0711177B1 (de)
JP (1) JPH09500896A (de)
KR (1) KR960703623A (de)
AT (1) ATE361760T1 (de)
AU (1) AU693799B2 (de)
CA (1) CA2167480A1 (de)
DE (1) DE69434970T2 (de)
GB (1) GB9315494D0 (de)
HU (1) HUT73979A (de)
NZ (1) NZ268934A (de)
WO (1) WO1995003830A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9501052D0 (en) * 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
GB0220319D0 (en) 2002-09-02 2002-10-09 Cancer Res Campaign Tech Enzyme activated self-immolative nitrogen mustard drugs
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US12178830B2 (en) 2017-06-30 2024-12-31 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB915454A (en) * 1960-06-28 1963-01-16 Nat Res Dev Nitrogen mustards
US5238922A (en) * 1991-09-30 1993-08-24 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5340828A (en) * 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
CA2122036C (en) * 1991-10-23 2002-09-17 Gillian Anlezark Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form
US5420157A (en) * 1991-12-16 1995-05-30 Merck & Co., Inc. Inhibitors of farnesyl protein transferase or prodrugs thereof
US5260479A (en) * 1991-12-16 1993-11-09 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5245061A (en) * 1991-12-16 1993-09-14 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
GB2264492B (en) * 1992-02-27 1996-09-25 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
ATE361759T1 (de) * 1993-07-15 2007-06-15 Cancer Res Campaign Tech Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können

Also Published As

Publication number Publication date
EP0711177A1 (de) 1996-05-15
AU7233394A (en) 1995-02-28
AU693799B2 (en) 1998-07-09
DE69434970D1 (de) 2007-06-21
HUT73979A (en) 1996-10-28
NZ268934A (en) 1997-12-19
HU9503984D0 (en) 1996-03-28
GB9315494D0 (en) 1993-09-08
KR960703623A (ko) 1996-08-31
WO1995003830A2 (en) 1995-02-09
US5770731A (en) 1998-06-23
CA2167480A1 (en) 1995-02-09
EP0711177B1 (de) 2007-05-09
WO1995003830A3 (en) 1995-04-06
JPH09500896A (ja) 1997-01-28
DE69434970T2 (de) 2008-01-31

Similar Documents

Publication Publication Date Title
BR9106819A (pt) Polimeros contendo unidades diester,processo para a preparacao de um polimero e compostos
FI970246A7 (fi) Dihydrobentsofuraanit
DK0941218T3 (da) Antithrombotiske organiske nitrater
MX9307052A (es) Derivados del taxano sustituidos con furil-carbonilo o tienil-carbonilo y composiciones farmaceuticas que los contienen.
PL339701A1 (en) Acylosulphamoybenzamides, crop protection products containing them and method of obtaining such crop protection products
UA26427A (uk) Похідhі ксаhтиhу у вигляді суміші ізомерів або іhдивідуальhих ізомерів, що мають властивість аhтагоhіста адеhозиhу
DE69326250D1 (de) Neuropeptide y antagoniste
ES2036562T3 (es) Un procedimiento para produccion de un derivado de pirrolidinamida.
HUP9801387A2 (hu) Antibakteriális cefalosporinszármazékok
ATE205072T1 (de) Kosmetische zusammensetzung enthaltend eine indigotyp-verbindung
ATE361760T1 (de) Verbesserungen in der bereitung von prodrogen
ATE161717T1 (de) Antivirale mittel
BR9908105A (pt) Composto de amida cìclica.
DE59404792D1 (de) Wässrige polymerisatzubereitungen
ATE260285T1 (de) Geschützte phenylalkylsilane
HUP9802764A2 (hu) Guanidino-proteáz-inhibitorok
ES2177816T3 (es) Derivados de azahexano como isosteros de sustrato de aspartato proteasas retroviricas.
DE69017584D1 (de) Pflanzenschutzzubereitungen, tierärztliche und zusätzliche herstellungen.
FI940731A0 (fi) Amiditetratsolit ACAT-inhibiitoreina
KR970703761A (ko) 암 전이 억제제(cancerous metastasis inhibitor)
EP0420116A3 (en) Novel substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
IL109051A0 (en) Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
MX9305765A (es) Procedimiento para la preparacion estereoselectiva de un derivado de la beta-fenilisoserina y produc to por medio del mismo.
FR2707496B1 (fr) Compositions pharmaceutiques antiradicalaires et/ou antilipoperoxydantes et/ou hépatotropes.
FR2707634B1 (fr) Procédé de préparation de N-carbonylarylimines utiles dans la synthèse de taxoïdes thérapeutiquement actifs.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties